These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31449117)

  • 21. Electrochemical skin conductance in hereditary amyloidosis related to transthyretin V30M - a promising tool to assess treatment efficacy?
    Castro J; Costa J; de Castro I; Conceição I
    Amyloid; 2018 Dec; 25(4):267-268. PubMed ID: 30773060
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation.
    Bulinski C; Discher T; Rutsatz W; Assmus B; Krämer HH
    J Neurol; 2022 Jul; 269(7):3912-3914. PubMed ID: 35124750
    [No Abstract]   [Full Text] [Related]  

  • 23. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y
    J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe heart disease in an unusual case of familial amyloid polyneuropathy type I.
    Oliveira Santos M; Brito D
    Rev Port Cardiol; 2013 Sep; 32(9):729-33. PubMed ID: 23993291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.
    Damy T; Judge DP; Kristen AV; Berthet K; Li H; Aarts J
    J Cardiovasc Transl Res; 2015 Mar; 8(2):117-27. PubMed ID: 25743445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy.
    Carr AS; Pelayo-Negro AL; Jaunmuktane Z; Scalco RS; Hutt D; Evans MR; Heally E; Brandner S; Holton J; Blake J; Whelan CJ; Wechalekar AD; Gillmore JD; Hawkins PN; Reilly MM
    Neuromuscul Disord; 2015 Jun; 25(6):511-5. PubMed ID: 25819286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
    Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
    J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis.
    Buxbaum JN; Brannagan T; Buades-Reinés J; Cisneros E; Conceicao I; Kyriakides T; Merlini G; Obici L; Plante-Bordeneuve V; Rousseau A; Sekijima Y; Imai A; Waddington Cruz M; Yamada M
    Amyloid; 2019 Mar; 26(1):10-14. PubMed ID: 30675806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tafamidis in hereditary ATTR amyloidosis - our experience on monitoring the ocular manifestations.
    Casal I; Monteiro S; Beirão JM
    Amyloid; 2016 Dec; 23(4):262-263. PubMed ID: 27748624
    [No Abstract]   [Full Text] [Related]  

  • 30. A designer drug for amyloid polyneuropathy.
    Chalk C
    Neurology; 2012 Aug; 79(8):730-1. PubMed ID: 22843277
    [No Abstract]   [Full Text] [Related]  

  • 31. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
    Matsushima M; Yabe I; Tsuda M; Sakakibara M; Shimamura T; Sasaki H
    Intern Med; 2017 Dec; 56(23):3231-3235. PubMed ID: 28943540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?
    Falk RH
    Eur Heart J; 2019 Mar; 40(12):1009-1012. PubMed ID: 30668704
    [No Abstract]   [Full Text] [Related]  

  • 33. [The ATTR-ACT trial].
    Rapezzi C; Gagliardi C; Milandri A
    G Ital Cardiol (Rome); 2019 Jun; 20(6):335-337. PubMed ID: 31184318
    [No Abstract]   [Full Text] [Related]  

  • 34. Tafamidis dramatically improved severe proteinuria in a patient with TTR V30M hereditary ATTR amyloidosis.
    Ikeda SI; Hineno A; Ichikawa T; Makino M
    Amyloid; 2019 Jun; 26(2):99-100. PubMed ID: 31090446
    [No Abstract]   [Full Text] [Related]  

  • 35. [What gnaws at the heart and gets on the nerves].
    Kristen AV
    Internist (Berl); 2018 Nov; 59(11):1208-1213. PubMed ID: 30039176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Huber P; Flynn A; Sultan MB; Li H; Rill D; Ebede B; Gundapaneni B; Schwartz JH
    Amyloid; 2019 Dec; 26(4):203-209. PubMed ID: 31353964
    [No Abstract]   [Full Text] [Related]  

  • 37. Annual electrocardiograms consistent with silent progression of cardiac involvement in sporadic familial amyloid polyneuropathy: a case report.
    Takigawa M; Hashimura K; Ishibashi-Ueda H; Yamada N; Kiso K; Nanasato M; Yoshida Y; Hirayama H
    Intern Med; 2010; 49(2):139-44. PubMed ID: 20075578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is it better than it seems or just good enough? The tafamidis saga.
    de Carvalho M
    Muscle Nerve; 2012 Dec; 46(6):839-40. PubMed ID: 23042137
    [No Abstract]   [Full Text] [Related]  

  • 39. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
    Sekijima Y
    Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lead optimization of resilient next-generation transthyretin stabilizers for multiple target-product profiles: approaching the CNS.
    Simões CJV; Almeida ZL; Cardoso AL; Bezerra F; Almeida MR; Beirão J; Pinho E Melo TMVD; Saraiva MJ; Brito RMM
    Amyloid; 2019; 26(sup1):77-78. PubMed ID: 31343302
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.